Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02074605 · ClinicalTrials.gov registry record
Cognitive Effects of Interferon in Patients With Melanoma
A clinical trial, sponsored by University of Arizona.
- Completed
- Registry status
- 36
- Enrollment target
NCT02074605 is a clinical trial that has completed, run by University of Arizona. The registered enrollment target is 36 participants.
The verdict
NCT02074605 has completed, sponsored by University of Arizona.
- COMPLETED
- Registry status
- 36 participants
- Enrollment target
Study Summary
Interferon alpha is the only approved adjuvant biologic therapy for individuals diagnosed with high risk malignant melanoma (stage 2 or 3). There is evidence that interferon has some adverse cognitive effects on patients, but there are limited data. The investigators hypothesis is that compared to patients with melanoma who do not receive interferon, patients who have melanoma and are treated with interferon will show an objective decrease in performance on neurocognitive assessment. This study will enroll patients with melanoma who qualify for interferon, and either decide to undergo interferon treatment or choose watchful waiting instead. All patients will be assessed with a cognitive testing battery twice. Observation patients will undergo testing at their first appointment in which they consent to the study, as well as at their next physician visit, approximately 3 months from the first visit. Interferon patients will be tested immediately prior to starting interferon, as well as immediately after completing high dose interferon.
Interventions
- BIOLOGICAL Interferon alpha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2008-07 |
| Est. Completion | 2010-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02074605
The ClinicalTrials.gov registry entry for NCT02074605 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arizona, which has 349 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Interferon alpha is the first listed.
NCT02074605 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02074605 about?
NCT02074605 is a clinical study titled "Cognitive Effects of Interferon in Patients With Melanoma". Interferon alpha is the only approved adjuvant biologic therapy for individuals diagnosed with high risk malignant melanoma (stage 2 or 3). There is evidence that interferon has some adverse cognitive effects on patients, but there are limited data. The investigators hypothesis is that compared to p...
What is the current status of trial NCT02074605?
This trial is currently completed. The enrollment target is 36 participants. The study started on 2008-07. Estimated completion is 2010-05.
What interventions are being tested in trial NCT02074605?
The interventions under investigation include: Interferon alpha (BIOLOGICAL).
Who is sponsoring clinical trial NCT02074605?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.